STOCKHOLM, Oct. 20,
2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR)
and (Stockholm: MVIR), a pharmaceutical company focused on
developing innovative treatments for cancer in areas of high unmet
medical need, announced today that the company's board member
Anette Lindqvist has informed the
board of directors that she is leaving her position due to personal
reasons.
"We respect Anette's decision and at the same time want to
thank her for her meritorious efforts. With her competence and
experience, she has been a valuable force in the board's work,"
says Uli Hacksell, chairman of Medivir's board of directors.
Medivir's nomination committee has initiated the search for a
replacement for Anette
Lindqvist.
For additional information, please contact;
Uli Hacksell, Chairman of the Board, Medivir AB
Telephone: +46 8 5468 3100
E-mail: info@medivir.com
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
fostroxacitabine bralpamide (fostrox), a pro-drug designed to
selectively treat liver cancer and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com.
The following files are available for download:
|
https://mb.cision.com/Main/652/3857989/2375823.pdf
|
Press Release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/change-in-medivirs-board-of-directors-301963205.html
SOURCE Medivir